2025-12-03 - Analysis Report
Okay, let's break down the analysis of Hims & Hers Health Inc. (HIMS).

**0) Report Structure:**

We'll start with the raw data, then move into simple analysis, pulling information from each section.

**1) Return Rate Comparison (vs. S&P 500 - VOO):**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc is a telehealth company offering personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 138.16%
*   **VOO Cumulative Return:** 74.32%
*   **Divergence:** 82.8
*   **Relative Divergence:** 41.4

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) with a cumulative return of 138.16% compared to VOO's 74.32%. The divergence is 82.8, meaning HIMS's return exceeds VOO's by that percentage.  The relative divergence of 41.4 suggests that while the divergence is positive, there's room for it to grow given past performance.  It sits in the middle of the historical range.

**Alpha, Beta Analysis Table:**

|            | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
| :--------- | :------ | :------ | :----- | :---- | :----- |
| 2019-2021  | -42.0%  | 74.4%  | -81.0% | 0.0  | 1.5   |
| 2020-2022  | -19.0%  | 78.6%  | -18.0% | -0.0 | 1.5   |
| 2021-2023  | -65.0%  | 78.6%  | -67.0% | -0.1 | 2.0   |
| 2022-2024  | 119.0%  | 79.4%  | 98.0%  | -0.0 | 5.5   |
| 2023-2025  | 143.0%  | 80.8%  | 78.0%  | 0.1  | 8.4   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR varies greatly. The company had significant negative growth in the earlier periods but has seen substantial positive growth in recent years (2022-2025).
*   **MDD (Maximum Drawdown):**  The MDD is consistently high, indicating substantial risk and price volatility.  Investors need to be comfortable with large potential drops in value.
*   **Alpha:** Alpha measures the stock's performance relative to a benchmark (presumably the market).  Negative alpha in early periods indicates underperformance.  The positive alpha in the most recent periods (2022-2025) indicates outperformance.
*   **Beta:** Beta measures the stock's volatility relative to the market. A beta near 0 suggests the stock is uncorrelated to the market.
*   **Cap(B) (Market Capitalization in Billions):** Market cap has grown substantially, indicating investor confidence and company expansion.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 36.8895
*   **Last Market Data:**  Price: 36.9334, Previous Close: 37.51, Change: -1.54
*   **5-day SMA:** 37.9839
*   **20-day SMA:** 38.701
*   **60-day SMA:** 48.2109

**Analysis:**  The current price is below all three moving averages (5-day, 20-day, and 60-day). This suggests a short-term, medium-term, and long-term downward trend. The negative change in the last market indicates recent selling pressure.

**3) Indicators:**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 40.11 (Below 50 is considered bearish and below 30 is oversold)
*   **PPO (Percentage Price Oscillator):** 1.1897
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** 7.5 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** 18.1% (Excess return compared to S&P 500, long-term)

**Analysis:**

*   The MRI suggests a medium investment level, which is somewhat conservative.
*   The RSI is below 50, indicating bearish momentum.  It's not yet in oversold territory, suggesting further downside is possible.
*   The PPO being slightly positive could indicate a change in trend.
*   The Hybrid Signal recommends a fully invested position. The recommendation seems aggressive.
*   The 20-day relative divergence change indicates a short-term upward movement.
*   The expected return of 18.1% is optimistic, suggesting potential for long-term outperformance.

**4) Recent News & Significant Events:**

*   **Share Repurchase Program:** Hims & Hers announced a $250 million share repurchase program.  This is generally seen as a positive sign, as it indicates the company believes its stock is undervalued and is willing to use its cash to buy back shares.
*   **Price Decline:** There's news highlighting a significant price drop (15.6% in 3 months). This likely contributes to the bearish signals seen in the technical indicators.
*   **Analyst Opinions:** Articles discuss Q3 earnings, market challenges, and whether the buyback can shift the company's narrative.
*   **Potential Deal:** News mentions a potential deal with Novo, which could have driven a price reversal.

**4-2) Analyst Opinions:**

*   **Mean Rating:** - (~-) (No consensus)
*   **Number of Opinions:** 11
*   **Target Price (avg/high/low):** 44.82 / 85.00 / 25.00
*   **Recent Rating Changes:** No changes available

**Analysis:** Analyst opinions are unclear. The average target price ($44.82) is higher than the current price, suggesting potential upside.  However, the wide range between the high and low targets ($85.00 and $25.00) indicates significant uncertainty about the stock's future.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
| :--------- | :--- | :---------- |
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

**Analysis:** Revenue has been generally increasing, which is positive. EPS has been volatile.  It's important to note there's a duplicate entry for 2025-11-03. Revenue appears to be growing.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-09-30 | $0.60B    | 73.80%       |
| 2025-06-30 | $0.54B    | 76.39%       |
| 2025-03-31 | $0.59B    | 73.50%       |
| 2024-12-31 | $0.48B    | 76.81%       |
| 2024-09-30 | $0.40B    | 79.16%       |

**Analysis:**  Revenue is showing a clear upward trend. Profit margins are consistently high, indicating strong pricing power and cost management.

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
| :--------- | :-------- | :----- |
| 2025-09-30 | $0.58B    | 2.72%  |
| 2025-06-30 | $0.56B    | 7.55%  |
| 2025-03-31 | $0.55B    | 9.01%  |
| 2024-12-31 | $0.48B    | 5.46%  |
| 2024-09-30 | $0.44B    | 17.18% |

**Analysis:**  Equity is increasing, suggesting the company is building value. However, ROE (Return on Equity) has decreased sharply in the most recent quarter.

**7) Comprehensive Analysis (Summary):**

HIMS has demonstrated significant outperformance compared to the S&P 500, but it also exhibits high volatility, which is reflected in the high MDD. While the recent price action shows a downward trend, the financial performance reveals strong and growing revenue, and high profit margins.

**Key Positives:**

*   **Strong Revenue Growth:** HIMS is consistently increasing its revenue, indicating successful market penetration and customer acquisition.
*   **High Profit Margins:** The company's impressive profit margins demonstrate efficient operations and pricing power.
*   **Share Repurchase Program:** This suggests the company believes its stock is undervalued.

**Key Concerns:**

*   **High Volatility:** The high MDD and fluctuating CAGR indicate a high-risk investment.
*   **Recent Price Decline:** The stock is currently trading below its moving averages, reflecting recent selling pressure.
*   **Decreasing ROE:**  The recent drop in ROE is a concerning trend that needs to be monitored.
*   **Analyst Uncertainty:** The wide range in analyst target prices reflects uncertainty about the stock's future.

**Overall Recommendation:**

The data paints a mixed picture. HIMS is a growth company with strong financial fundamentals and long-term potential. However, it's also a high-risk, high-reward investment with significant price volatility and recent negative momentum.

Given the MRI of 0.9, a **medium investment** might be warranted for investors with a high risk tolerance and a long-term investment horizon. A more cautious approach would involve waiting for a stabilization in the stock price and a reversal of the downward trend before initiating a position. Investors should carefully consider their own risk tolerance and investment goals before investing in HIMS.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.